Cutting Edge Science

Skip To Main Content

This website is intended exclusively for healthcare professionals residing and/or working in Qatar.

Campus

Login
Registration

Science
Asthma
Atopic Dermatitis
Bullous Pemphigoid
Chronic Obstructive Pulmonary Disease
Diabetes
Eosinophilic Esophagitis
Immune Thrombocytopenia ITP
Multiple Myeloma
Multiple Sclerosis
Nasal Polyps
Neurological Disorders
Prurigo Nodularis
Immunology-Pipeline

Acquired Thrombotic Thrombocytopenic Purpura (ATTP)
Hemophilia

Cardiovascular
Atherothrombosis
Dyslipidemia
Hypertension
Thrombosis

Rare Diseases
Gaucher
Fabry
Pompe
ASMD

Vaccines
Influenza
RSV
Mass Gathering

Rhinology
Cutting Edge Science

Patient Support
Atopic Dermatitis
Cardiovascular
Diabetes
Nasal Polyps
Rare Diseases

Vaccines
RSV

Product
Adacel®
Cerezyme®
Lemtrada®
Myozyme®
Nexviazyme
Solian®
Xatral®
Xenpozyme®

Aubagio®
Aubagio vs Ofatumumab

Beyfortus®
International Recommendation
Conferences
Real World Evidence
Clinical Experience

Cablivi®
aTTP Sphere Digital Case Library
Cablivi® aTTP Patients Voice

Clexane®
Surgical Patients
Hemodialysis

Dupixent®
Prurigo Nodularis
Atopic Dermatitis
Dupixent® COPD
Dupixent Asthma
Nasal Polyps

Fabrazyme®
Quantifying the Effect of Fabrazyme
Canadian Fabry Disease Initiative
Long Term Renal Function

Praluent®

Praluent®
LDL-C Control
LDL-C Control
LDL-C Control
LDL-C Control

Soliqua®
For a Peaceful Ramadan
Soliqua SoliD®
Soliqua Easy Start®
Soliqua Guidelines®
Soliqua Data Set®
Soliqua Simplicity®
Soliqua Safety®
Soliqua®
Post-GLP Podcast: needs of patients on GLP-1 RA with basal insulin
Soliqua Unmet Needs Video
Meet The Expert
Reimbursement
Limitations of Premixed Insulin

Toujeo®
Toujeo for a Peaceful Ramadan
Wall of Evidence
How to Start
Time in Range
Second generation basal insulin in advancing T2D therapy
Timely insulin initiation to limit disease progression
Meet the Expert

Toujeo T1DM
OneCare
Edition Junior
UltraFlexi-1
Type-1 Meta Analysis
Guidelines

Toujeo T2DM
Deliver-G
Guidelines

Toujeo Innovation
Toujeo Upgrade to Win

Campus

Science
Asthma
Atopic Dermatitis
Bullous Pemphigoid
Chronic Obstructive Pulmonary Disease
Diabetes
Eosinophilic Esophagitis
Immune Thrombocytopenia ITP
Multiple Myeloma
Multiple Sclerosis
Nasal Polyps
Neurological Disorders
Prurigo Nodularis
Immunology-Pipeline

Acquired Thrombotic Thrombocytopenic Purpura (ATTP)
Hemophilia

Cardiovascular
Atherothrombosis
Dyslipidemia
Hypertension
Thrombosis

Rare Diseases
Gaucher
Fabry
Pompe
ASMD

Vaccines
Influenza
RSV
Mass Gathering

Rhinology
Cutting Edge Science

Patient Support
Atopic Dermatitis
Cardiovascular
Diabetes
Nasal Polyps
Rare Diseases

Vaccines
RSV

Product
Adacel®
Cerezyme®
Lemtrada®
Myozyme®
Nexviazyme
Solian®
Xatral®
Xenpozyme®

Aubagio®
Aubagio vs Ofatumumab

Beyfortus®
International Recommendation
Conferences
Real World Evidence
Clinical Experience

Cablivi®
aTTP Sphere Digital Case Library
Cablivi® aTTP Patients Voice

Clexane®
Surgical Patients
Hemodialysis

Dupixent®
Prurigo Nodularis
Atopic Dermatitis
Dupixent® COPD
Dupixent Asthma
Nasal Polyps

Fabrazyme®
Quantifying the Effect of Fabrazyme
Canadian Fabry Disease Initiative
Long Term Renal Function

Praluent®

Praluent®
LDL-C Control
LDL-C Control
LDL-C Control
LDL-C Control

Soliqua®
For a Peaceful Ramadan
Soliqua SoliD®
Soliqua Easy Start®
Soliqua Guidelines®
Soliqua Data Set®
Soliqua Simplicity®
Soliqua Safety®
Soliqua®
Post-GLP Podcast: needs of patients on GLP-1 RA with basal insulin
Soliqua Unmet Needs Video
Meet The Expert
Reimbursement
Limitations of Premixed Insulin

Toujeo®
Toujeo for a Peaceful Ramadan
Wall of Evidence
How to Start
Time in Range
Second generation basal insulin in advancing T2D therapy
Timely insulin initiation to limit disease progression
Meet the Expert

Toujeo T1DM
OneCare
Edition Junior
UltraFlexi-1
Type-1 Meta Analysis
Guidelines

Toujeo T2DM
Deliver-G
Guidelines

Toujeo Innovation
Toujeo Upgrade to Win

Login
Registration

Science
Rhinology
Cutting Edge Science

Sort by

Filters

Reset

Therapeutical Areas
- Anti-Infectives
- Asthma
- Atherothrombosis
- Atopic Dermatitis
- Diabetes
- Dyslipidemia
- Eosinophilic Esophagitis
- Influenza
- Meningitis
- Multiple Sclerosis
- Nasal Polyps
- Neurological Disorders
- Oncology and Rare Blood Disorder
- Pertussis & Polio
- Prurigo Nodularis
- Rare Diseases
- RSV
- Thrombosis
- Mass Gathering
- Rhinology

Type of Content
- Watch
- Listen
- Read

Ministry of Health organizes "KiDS" program at Expo 2020 Dubai to promote diabetes awareness at schools

Learn more

Pre-Ramadan assessment and Risk calculation for people with diabetes who want to fast during Ramadan

Learn more

Patients Factors & Impacts

Learn more

Myeloma Facts

Learn more

What is your experience with Dupixent in your practice?

Learn more

Edition Junior Study - Helping patients with type 1 diabetes (T1D) to find better treatment options

Learn more

Hear from an expert on how does Dupixent target Underlying Type 2 Inflammation?

Learn more

Hear from an expert on would you consider a biologic for a Surgery-naïve Patient with CRS with Nasal Polyps?

Learn more

Type 2 Inflammation is the underlying cause of CRSwNP in 80% of Patients.

Learn more

Innovation of Iglarlexi in Intensification

Learn more

Innovation of Iglarlexi in Intensification

Learn more

Ultimate Need for Intensification

Learn more

«
‹
10
11
12
13
14
15
16
17
18
19
›
»

Campus

Privacy Notice Update

We have updated our Privacy Notice for Healthcare Professionals to improve your experience collaborating with us, maintain high standards of privacy and ultimately strengthen the trust you place in us.

Key improvements include enhanced clarity on why and how Sanofi processes your personal data.

Back to top

Legal notice Cookie policy Privacy Policy Sitemap Change country

© Sanofi 2004- - All rights reserved

MAT-QA-2600010/V1/APR2026

SANOFI, Level 3, One JLT, Jumeirah Lake Towers (JLT), DMCC, PO Box 53899, Dubai, UAE Tel.: +971 4 550 3600 | Fax: +971 4 5521050

For further medical information, please contact: For UAE ✆ 800 MEDICAL Toll-Free Number. For all Gulf countries +971 45 50 38 63 or email: medical-information.gulf@sanofi.com.

To report an adverse event or drug reaction, please contact us on: 24/ 7 Pharmacovigilance reporting number: +971 561747001 e-mail: gulf.pharmacovigilance@sanofi.com